AZITHROMYCIN 500mg. IP

A broad-spectrum antimicrobial drug is used to treat a variety of bacterial infections. (Brendan J McMullan, 2015) Exerts bacteriostatic activity against many gram-positive and gram-negative bacteria. (Brendan J McMullan, 2015) Shows anti-inflammatory and immunomodulatory effects in chronic airway inflammatory diseases. (Jianmeng Zhou, 2020) A promising candidate for the prevention of exacerbations in patients with non-cystic fibrosis bronchiectasis. (Conroy Wong, 2012) Reduces asthma exacerbations and improves the quality of life in adults with persistent uncontrolled asthma. (Peter G Gibson, 2017) A well-tolerated agent is associated with significant reductions in exacerbation and length of hospital stay in patients with severe chronic obstructive pulmonary disease. (Xavier Pomares, 2011) More active than erythromycin against many gram-negative pathogens and several other pathogens, notably Haemophilus influenzae, H. parainfluenzae, Moraxella catarrhalis, Neisseria gonorrhoeae. (D H Peters, 1992) A potential therapeutic outpatient treatment option for adults with uncomplicated enteric fever. (Celina Jin, 2019) A convenient alternative for the treatment of typhoid fever. (R W Frenck Jr, 2000) An effective therapy for typhoid fever in subjects with chloramphenicol-resistant S. typhi infection. (T Butler, 1999)